Vaccination therapy for inflammatory bowel disease

References

• Alatab S, Sepanlou SG, Ikuta K, Vahedi H, Bisignano C, Safiri S, Sadeghi A, Nixon MR, Abdoli A, Abolhassani H, et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol. 2020;5(1):17–9. doi:10.1016/S2468-1253(19)30333-4.
   PubMed Web of Science ®Google Scholar
• Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, Panaccione R, Ghosh S, Wu JCY, Chan FKL, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390(10114):2769–78. doi:10.1016/S0140-6736(17)32448-0.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Liu J, Han X, Jiang H, Zhang L, Hu J, Shi L, Li J. Long-term trends in the burden of inflammatory bowel disease in China over three decades: a joinpoint regression and age-period-cohort analysis based on GBD 2019. Front Public Health. 2022;10:994619. doi:10.3389/fpubh.2022.994619.
   PubMed Web of Science ®Google Scholar
• Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021;18(1):56–66. doi:10.1038/s41575-020-00360-x.
   PubMed Web of Science ®Google Scholar
• Cai Z, Wang S, Li J. Treatment of inflammatory bowel disease: a comprehensive review. Front Med. 2021;8:765474. doi:10.3389/fmed.2021.765474.
   Web of Science ®Google Scholar
• Mao R, Hu P-J. The future of IBD therapy: where are we and where should we go next? Digest Dis. 2016;34(1–2):175–9. doi:10.1159/000443135.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Jarr K, Layton C, Gardner CD, Ashouri JF, Abreu MT, Sinha SR. Therapeutic implications of diet in inflammatory bowel disease and related immune-mediated inflammatory diseases. Nutrients. 2021;13(3):890. doi:10.3390/nu13030890.
   PubMed Web of Science ®Google Scholar
• Mikocka-Walus A, Prady SL, Pollok J, Esterman AJ, Gordon AL, Knowles S, Andrews JM. Adjuvant therapy with antidepressants for the management of inflammatory bowel disease. Cochrane Database Syst Rev. 2019;4(4):CD012680. doi:10.1002/14651858.CD012680.pub2.
   PubMedGoogle Scholar
• Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Official Am J Gastroentero. 2011;106(4):685. doi:10.1038/ajg.2011.103.
   PubMed Web of Science ®Google Scholar
• Lichtenstein L, Ron Y, Kivity S, Ben-Horin S, Israeli E, Fraser GM, Dotan I, Chowers Y, Confino-Cohen R, Weiss B. Infliximab-related infusion reactions: systematic review. J Crohns Colitis. 2015;9(9):806–15. doi:10.1093/ecco-jcc/jjv096.
   PubMed Web of Science ®Google Scholar
• Conrad MA, Stein RE, Maxwell EC, Albenberg L, Baldassano RN, Dawany N, Grossman AB, Mamula P, Piccoli DA, Kelsen JR. Vedolizumab therapy in severe pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(10):2425–31. doi:10.1097/MIB.0000000000000918.
   PubMed Web of Science ®Google Scholar
• Holder-Murray J, Marsicovetere P, Holubar SD. Minimally invasive surgery for inflammatory bowel disease. Inflamm Bowel Dis. 2015;21(6):1443–58. doi:10.1097/MIB.0000000000000316.
   PubMed Web of Science ®Google Scholar
• Zangenberg MS, El-Hussuna A. Psychiatric morbidity after surgery for inflammatory bowel disease: a systematic review. World J Gastroenterol. 2017;23(48):8651–9. doi:10.3748/wjg.v23.i48.8651.
   PubMed Web of Science ®Google Scholar
• Fuglestad MA, Thompson JS. Inflammatory bowel disease and short bowel syndrome. Surg Clin North Am. 2019;99(6):1209–21. doi:10.1016/j.suc.2019.08.010.
   PubMed Web of Science ®Google Scholar
• Dudley MZ, Halsey NA, Omer SB, Orenstein WA, O’Leary ST, Limaye RJ, Salmon DA. The state of vaccine safety science: systematic reviews of the evidence. Lancet Infect Dis. 2020;20(5):e80–e9. doi:10.1016/S1473-3099(20)30130-4.
   PubMed Web of Science ®Google Scholar
• Doherty M, Buchy P, Standaert B, Giaquinto C, Prado-Cohrs D. Vaccine impact: benefits for human health. Vaccine. 2016;34(52):6707–14. doi:10.1016/j.vaccine.2016.10.025.
   PubMed Web of Science ®Google Scholar
• Klugman KP, Black S. Impact of existing vaccines in reducing antibiotic resistance: primary and secondary effects. Proc Natl Acad Sci USA. 2018;115(51):12896–901. doi:10.1073/pnas.1721095115.
   PubMed Web of Science ®Google Scholar
• Semerano L, Assier E, Boissier M-C. Anti-cytokine vaccination: a new biotherapy of autoimmunity? Autoimmun Rev. 2012;11(11):785–6. doi:10.1016/j.autrev.2012.02.003.
   PubMed Web of Science ®Google Scholar
• Spohn G, Schori C, Keller I, Sladko K, Sina C, Guler R, Schwarz K, Johansen P, Jennings GT, Bachmann MF. Preclinical efficacy and safety of an anti-IL-1β vaccine for the treatment of type 2 diabetes. Mol Ther Methods Clin Dev. 2014;1. doi:10.1038/mtm.2014.48.
   PubMed Web of Science ®Google Scholar
• Matsuoka K. Fecal microbiota transplantation for ulcerative colitis. Immunol Med. 2021;44(1):30–4. doi:10.1080/25785826.2020.1792040.
   PubMedGoogle Scholar
• Lobionda S, Sittipo P, Kwon HY, Lee YK. The role of gut microbiota in intestinal inflammation with respect to diet and extrinsic stressors. Microorganisms. 2019;7(8):271. doi:10.3390/microorganisms7080271.
   PubMed Web of Science ®Google Scholar
• Shen Z-H, Zhu C-X, Quan Y-S, Yang Z-Y, Wu S, Luo W-W, Tan B, Wang X-Y. Relationship between intestinal microbiota and ulcerative colitis: mechanisms and clinical application of probiotics and fecal microbiota transplantation. WJG. 2018;24(1):5–14. doi:10.3748/wjg.v24.i1.5.
   PubMed Web of Science ®Google Scholar
• Chen Y, Cui W, Li X, Yang H. Interaction between commensal bacteria, immune response and the intestinal barrier in inflammatory bowel disease. Front Immunol. 2021 April 18;12. doi:10.3389/fimmu.2021.761981.
   Web of Science ®Google Scholar
• Guan Q. A comprehensive review and update on the pathogenesis of inflammatory bowel disease. J Immunol Res. 2019;2019:1–16. doi:10.1155/2019/7247238.
   Web of Science ®Google Scholar
• Lissner D, Schumann M, Batra A, Kredel LI, Kühl AA, Erben U, May C, Schulzke JD, Siegmund B. Monocyte and M1 macrophage-induced barrier defect contributes to chronic intestinal inflammation in IBD. Inflamm Bowel Dis. 2015 Jun;21(6):1297–305. doi:10.1097/MIB.0000000000000384.
   PubMed Web of Science ®Google Scholar
• Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014 May;14(5):329–42. doi:10.1038/nri3661.
   PubMed Web of Science ®Google Scholar
• Agirman G, Yu KB, Hsiao EY. Signaling inflammation across the gut-brain axis. Science. 2021 Nov 26;374(6571):1087–92. doi:10.1126/science.abi6087.
   PubMed Web of Science ®Google Scholar
• Lee SH, Eun Kwon J, Cho M-L. Immunological pathogenesis of inflammatory bowel disease. Intest Res. 2018;16(1):26. doi:10.5217/ir.2018.16.1.26.
   PubMed Web of Science ®Google Scholar
• Michielan A, D’Incà R. Intestinal permeability in inflammatory bowel disease: pathogenesis, clinical evaluation, and therapy of leaky gut. Mediators Inflamm. 2015;2015:1–0. doi:10.1155/2015/628157.
   Web of Science ®Google Scholar
• He C, Shi Y, Wu R, Sun M, Fang L, Wu W, Liu C, Tang M, Li Z, Wang P, et al. miR-301a promotes intestinal mucosal inflammation through induction of IL-17A and TNF-α in IBD. Gut. 2016;65(12):1938–50. doi:10.1136/gutjnl-2015-309389.
   PubMed Web of Science ®Google Scholar
• Pouillon L, Bossuyt P, Peyrin-Biroulet L. Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease. Expert Opin Biol Ther. 2016;16(10):1277–90. doi:10.1080/14712598.2016.1203897.
   PubMed Web of Science ®Google Scholar
• Magro F, Portela F. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. BioDrugs. 2010;24(Suppl 1):3–14. doi:10.2165/11586290-000000000-00000.
   PubMed Web of Science ®Google Scholar
• Vulliemoz M, Brand S, Juillerat P, Mottet C, Ben-Horin S, Michetti P. On behalf of Swiss IBDnet, an official working group of the Swiss society of Gastroenterology. TNF-Alpha blockers in inflammatory bowel diseases: practical recommendations and a user’s guide: an update. Digestion. 2020;101 Suppl 1:16–26. doi:10.1159/000506898.
   PubMed Web of Science ®Google Scholar
• Zhang J, Cui Y, Wu Y, Wang H, Ke J. Prediction and identification of B-cell epitopes for tumor necrosis factor-α. Mol Med Rep. 2017;16(3):3439–44. doi:10.3892/mmr.2017.7007.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Negrini S, Pellecchio M, Greco M, Schiavi C, Giusti F, Puppo F. Update upon the infection risk in patients receiving TNF alpha inhibitors. Expert Opin Drug Saf. 2019;18(3):219–29. doi:10.1080/14740338.2019.1577817.
   PubMed Web of Science ®Google Scholar
• Le Buanec H, Delavallée L, Bessis N, Paturance S, Bizzini B, Gallo R, Zagury D, Boissier M-C. Tnfα kinoid vaccination-induced neutralizing antibodies to TNFα protect mice from autologous TNFα-driven chronic and acute inflammation. Proc Natl Acad Sci USA. 2006;103(51):19442–7. doi:10.1073/pnas.0604827103.
   PubMed Web of Science ®Google Scholar
• Collison J. Rheumatoid arthritis: paving the way for TNF vaccines. Nat Rev Rheumatol. 2016;12(12):692. doi:10.1038/nrrheum.2016.171.
   PubMedGoogle Scholar
• Zhang L, Wang J, Xu A, Zhong C, Lu W, Deng L, Li R. A rationally designed TNF-α epitope-scaffold Immunogen induces sustained antibody response and alleviates collagen-induced arthritis in mice. PloS One. 2016;11(9):e0163080. doi:10.1371/journal.pone.0163080.
   PubMed Web of Science ®Google Scholar
• Durez P, Vandepapeliere P, Miranda P, Toncheva A, Berman A, Kehler T, Mociran E, Fautrel B, Mariette X, Dhellin O, et al. Therapeutic vaccination with TNF-Kinoid in TNF antagonist-resistant rheumatoid arthritis: a phase II randomized, controlled clinical trial. PloS One. 2014;9(12):e113465. doi:10.1371/journal.pone.0113465.
   PubMed Web of Science ®Google Scholar
• Sun Y, Pan W, Zhang J, Cui Y, Wang H, Ru G, Chen L. Complex TNF-α B cell epitope MAP vaccine alleviates murine ulcerative colitis. Int J Mol Med. 2019 Sep;44(3):1106–16. doi:10.3892/ijmm.2019.4271.
   PubMed Web of Science ®Google Scholar
• Almradi A, Hanzel J, Sedano R, Parker CE, Feagan BG, Ma C, Jairath V. Clinical trials of IL-12/IL-23 inhibitors in inflammatory bowel disease. BioDrugs. 2020;34(6):713–21. doi:10.1007/s40259-020-00451-w.
   PubMed Web of Science ®Google Scholar
• Yanagibashi T, Satoh M, Nagai Y, Koike M, Takatsu K. Allergic diseases: from bench to clinic - contribution of the discovery of interleukin-5. Cytokine. 2017;98:59–70. doi:10.1016/j.cyto.2016.11.011.
   PubMed Web of Science ®Google Scholar
• Hohenberger M, Cardwell LA, Oussedik E, Feldman SR. Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease. J Dermatolog Treat. 2018;29(1):13–18. doi:10.1080/09546634.2017.1329511.
   PubMed Web of Science ®Google Scholar
• Guan Q, Warrington R, Moreno S, Qing G, Weiss C, Peng Z. Sustained suppression of IL-18 by employing a vaccine ameliorates intestinal inflammation in TNBS-induced murine colitis. Future Sci OA. 2019;5(7):FSO405. doi:10.2144/fsoa-2018-0125.
   PubMed Web of Science ®Google Scholar
• Guan Q, Weiss CR, Wang S, Qing G, Yang X, Warrington RJ, Bernstein CN, Peng Z. Reversing ongoing chronic intestinal inflammation and fibrosis by sustained block of IL-12 and IL-23 using a vaccine in mice. Inflamm Bowel Dis. 2018;24(9):1941–52. doi:10.1093/ibd/izy142.
   PubMed Web of Science ®Google Scholar
• Assier E, Bessis N, Zagury JF, Boissier MC. IL-1 vaccination is suitable for treating inflammatory diseases. Front Pharmacol. 2017 Jan 31;8:6. doi:10.3389/fphar.2017.00006.
   PubMed Web of Science ®Google Scholar
• Srivastava V, Navabharath M, Gupta S, Singh SV, Ahmad S. Exploration of Solanum xanthocarpum Schrad. & Wendl. against mycobacterium avium subspecies paratuberculosis and assessment of its immunomodulatory and anti-inflammatory potential. Pharmaceuticals. 2022;15(11):1367. doi:10.3390/ph15111367.
   Web of Science ®Google Scholar
• Agrawal G, Borody T, Turner R, Leis S, Campbell J. Combining infliximab, anti-MAP and hyperbaric oxygen therapy for resistant fistulizing Crohn’s disease. Future Sci OA. 2015;1(4):FSO77. doi:10.4155/fso.15.77.
   PubMedGoogle Scholar
• Aitken JM, Phan K, Bodman SE, Sharma S, Watt A, George PM, Agrawal G, Tie ABM. A mycobacterium species for Crohn’s disease? Pathology. 2021 Dec;53(7):818–23. doi:10.1016/j.pathol.2021.03.003.
   PubMed Web of Science ®Google Scholar
• Agrawal G, Clancy A, Huynh R, Borody T. Profound remission in Crohn’s disease requiring no further treatment for 3-23 years: a case series. Gut Pathog. 2020;12:16. doi:10.1186/s13099-020-00355-8.
   PubMed Web of Science ®Google Scholar
• Khan S, Imran A, Malik A, Chaudhary AA, Rub A, Jan AT, Syed JB, Rolfo C. Bacterial imbalance and gut pathologies: association and contribution of E. coli in inflammatory bowel disease. Crit Rev Clin Lab Sci. 2019;56(1):1–17. doi:10.1080/10408363.2018.1517144.
   PubMed Web of Science ®Google Scholar
• Palmela C, Chevarin C, Xu Z, Torres J, Sevrin G, Hirten R, Barnich N, Ng SC, Colombel J-F. Adherent-invasive Escherichia coli in inflammatory bowel disease. Gut. 2018;67(3):574–87. doi:10.1136/gutjnl-2017-314903.
   PubMed Web of Science ®Google Scholar
• Daley A, Randall R, Darsley M, Choudhry N, Thomas N, Sanderson IR, Croft NM, Kelly P. Genetically modified enterotoxigenic Escherichia coli vaccines induce mucosal immune responses without inflammation. Gut. 2007;56(11):1550–6. doi:10.1136/gut.2006.112805.
   PubMed Web of Science ®Google Scholar
• Alexander KL, Zhao Q, Reif M, Rosenberg AF, Mannon PJ, Duck LW, Elson CO. Human microbiota flagellins drive adaptive immune responses in Crohn’s disease. Gastroenterology. 2021;161(2):522–35.e6. doi:10.1053/j.gastro.2021.03.064.
   PubMed Web of Science ®Google Scholar
• Tran HQ, Ley RE, Gewirtz AT, Chassaing B. Flagellin-elicited adaptive immunity suppresses flagellated microbiota and vaccinates against chronic inflammatory diseases. Nat Commun. 2019;10(1):5650. doi:10.1038/s41467-019-13538-y.
   PubMed Web of Science ®Google Scholar
• Rafii S, Butler JM, Ding B-S. Angiocrine functions of organ-specific endothelial cells. Nature. 2016;529(7586):316–25. doi:10.1038/nature17040.
   PubMed Web of Science ®Google Scholar
• Jeong J-H, Ojha U, Lee YM. Pathological angiogenesis and inflammation in tissues. Arch Pharm Res. 2021;44(1):1–15. doi:10.1007/s12272-020-01287-2.
   PubMed Web of Science ®Google Scholar
• Aguilar-Cazares D, Chavez-Dominguez R, Carlos-Reyes A, Lopez-Camarillo C, Hernadez de la Cruz ON, Lopez-Gonzalez JS. Contribution of angiogenesis to inflammation and cancer. Front Oncol. 2019;9:1399. doi:10.3389/fonc.2019.01399.
   PubMed Web of Science ®Google Scholar
• Koutroubakis IE, Tsiolakidou G, Karmiris K, Kouroumalis EA. Role of angiogenesis in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12(6). doi:10.1097/00054725-200606000-00012.
   Web of Science ®Google Scholar
• Danese S, Sans M, De La Motte C, Graziani C, West G, Phillips MH, Pola R, Rutella S, Willis J, Gasbarrini A, et al. Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology. 2006;130(7):2060–73. doi:10.1053/j.gastro.2006.03.054.
   PubMed Web of Science ®Google Scholar
• Sajib S, Zahra FT, Lionakis MS, German NA, Mikelis CM. Mechanisms of angiogenesis in microbe-regulated inflammatory and neoplastic conditions. Angiogenesis. 2018;21(1):1–14. doi:10.1007/s10456-017-9583-4.
   PubMed Web of Science ®Google Scholar
• Gardlik R, Bartonova A, Celec P. Therapeutic DNA vaccination and RNA interference in inflammatory bowel disease. Int J Mol Med. 2013;32(2):492–6. doi:10.3892/ijmm.2013.1388.
   PubMed Web of Science ®Google Scholar
• Scaldaferri F, Vetrano S, Sans M, Arena V, Straface G, Stigliano E, Repici A, Sturm A, Malesci A, Panes J, et al. VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology. 2009;136(2):585–95.e5. doi:10.1053/j.gastro.2008.09.064.
   PubMed Web of Science ®Google Scholar
• Rahat MA. Targeting angiogenesis with peptide vaccines. Front Immunol. 2019;10:1924. doi:10.3389/fimmu.2019.01924.
   PubMed Web of Science ®Google Scholar
• Simanovich E, Brod V, Rahat MA. Active vaccination with EMMPRIN-Derived multiple antigenic peptide (161-MAP) reduces angiogenesis in a dextran sodium sulfate (DSS)-induced colitis model. Front Immunol. 2018;9:2919. doi:10.3389/fimmu.2018.02919.
   PubMed Web of Science ®Google Scholar
• Linares PM, Chaparro M, Gisbert JP. Angiopoietins in inflammation and their implication in the development of inflammatory bowel disease. A review. J Crohns Colitis. 2014;8(3):183–90. doi:10.1016/j.crohns.2013.06.013.
   PubMed Web of Science ®Google Scholar
• Arai T, Lopes F. Potential of human helminth therapy for resolution of inflammatory bowel disease: the future ahead. Exp Parasitol. 2022;232:108189. doi:10.1016/j.exppara.2021.108189.
   PubMed Web of Science ®Google Scholar
• Abdoli A. Therapeutic potential of helminths and helminth-derived antigens for resolution of inflammation in inflammatory bowel disease. Arch Med Res. 2019;50(1):58–9. doi:10.1016/j.arcmed.2019.03.001.
   PubMed Web of Science ®Google Scholar
• Summers RW, Elliott DE, Qadir K, Urban JF, Thompson R, Weinstock JV. Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease. Am J Gastroenterol. 2003 Sep;98(9):2034–41. doi:10.1111/j.1572-0241.2003.07660.x.
   PubMed Web of Science ®Google Scholar
• Huang X, Zeng L-R, Chen F-S, Zhu J-P, Zhu M-H. Trichuris suis ova therapy in inflammatory bowel disease: a meta-analysis. Medicine. 2018;97(34):e12087. doi:10.1097/MD.0000000000012087.
   PubMed Web of Science ®Google Scholar
• Schölmerich J, Fellermann K, Seibold FW, Rogler G, Langhorst J, Howaldt S, Novacek G, Petersen AM, Bachmann O, Matthes H, et al. A randomised, Double-blind, placebo-controlled trial of Trichuris suis ova in active Crohn’s disease. J Crohn’s Colitis. 2017;11(4):390–9. doi:10.1093/ecco-jcc/jjw184.
   Google Scholar
• Capron M, Béghin L, Leclercq C, Labreuche J, Dendooven A, Standaert A, Delbeke M, Porcherie A, Nachury M, Boruchowicz A, et al. Safety of P28GST, a protein derived from a schistosome helminth Parasite, in patients with Crohn’s disease: a pilot study (ACROHNEM). J Clin Med. 2020;9(1):41. doi:10.3390/jcm9010041.
   Web of Science ®Google Scholar
• Sarazin A, Dendooven A, Delbeke M, Gatault S, Pagny A, Standaert A, Rousseaux C, Desreumaux P, Dubuquoy L, Capron M, et al. Treatment with P28GST, a schistosome-derived enzyme, after acute colitis induction in mice: decrease of intestinal inflammation associated with a down regulation of Th1/Th17 responses. PloS One. 2018;13(12):e0209681. doi:10.1371/journal.pone.0209681.
   PubMed Web of Science ®Google Scholar
• Löffler P. Review: vaccine myth-buster - cleaning up with prejudices and dangerous misinformation. Front Immunol. 2021;12:663280. doi:10.3389/fimmu.2021.663280.
   PubMed Web of Science ®Google Scholar
• Yu X, Mai Y, Wei Y, Yu N, Gao T, Yang J. Therapeutic potential of tolerance-based peptide vaccines in autoimmune diseases. Int Immunopharmacol. 2023;116:109740. doi:10.1016/j.intimp.2023.109740.
   PubMed Web of Science ®Google Scholar
• Sabatos-Peyton CA, Verhagen J, Wraith DC. Antigen-specific immunotherapy of autoimmune and allergic diseases. Curr Opin Immunol. 2010;22(5):609–15. doi:10.1016/j.coi.2010.08.006.
   PubMed Web of Science ®Google Scholar
• Larche M, Wraith DCM. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat Med. 2005;11(4 Suppl):S69–S76. doi:10.1038/nm1226.
   PubMed Web of Science ®Google Scholar
• Zhang Y-Z, Li Y-Y. Inflammatory bowel disease: pathogenesis. World J Gastroenterol. 2014;20(1):91–9. doi:10.3748/wjg.v20.i1.91.
   PubMed Web of Science ®Google Scholar
• Huang J-H, Wu C-W, Lien S-P, Leng C-H, Hsiao K-N, Liu S-J, Chen H-W, Siu L-K, Chong P. Recombinant lipoprotein-based vaccine candidates against C. difficile infections. J Biomed Sci. 2015;22(1):65. doi:10.1186/s12929-015-0171-x.
   PubMedGoogle Scholar
• Ma Y, Guan Q, Bai A, Weiss CR, Hillman CL, Ma A, Zhou G, Qing G, Peng Z. Targeting TGF-β1 by employing a vaccine ameliorates fibrosis in a mouse model of chronic colitis. Inflamm Bowel Dis. 2010 Jun;16(6):1040–50. doi:10.1002/ibd.21167.
   PubMed Web of Science ®Google Scholar